BARDA and the Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) established a Technology Investment Agreement with Retractable Technologies, Inc. (RTI) to expand RTI’s manufacturing capacity to produce safety needles and syringes in the United States.
By taking steps to increase the ability to produce safety needles and syringes in the U.S., the federal government can reduce the nation’s dependence on other countries to provide these potentially lifesaving supplies. This expansion is even more critical during the COVID-19 pandemic as existing supplies are used in routine healthcare and to treat the surge of COVID-19 patients.
HHS and DoD are working together as part of Operation Warp Speed to ensure the availability of needles and syringes. This effort supports expansion of RTI’s domestic manufacturing capacity by at least 50 percent within 12 months of award. Once the capacity to produce at least 350 million safety needles and syringe units per year is achieved, the U.S. government’s private industry partners will receive priority in purchasing these syringes and needles, needed to administer COVID-19 medical countermeasures, such as vaccines.
About Retractable Technologies, Inc.:
The following information is provided by company and does not indicate endorsement by the federal government of the company or its products.
Retractable Technologies, Inc. (RVP) is the leading manufacturer of automated retraction syringes. Its VanishPoint® syringes and EasyPoint® needles feature unique automated retraction technology that effectively reduces the risk of needlestick injuries to healthcare workers and patients, and provides for safe and efficient disposal. RTI’s innovative safety technology is used for vaccination campaigns and for injections throughout the U.S. and internationally. Retractable Technologies’ headquarters and manufacturing facilities are located in Little Elm, Texas.